Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesCorMedix Inc

CorMedix Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
5.3 USD -0.07 ( 1.30%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1560818
Market Cap
604.85M
P/E
3.63

Momentum Score

…

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.24
Low
5.42
High
52 Week Price Range
6.12
Low
13.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CorMedix is a clinical-stage biopharmaceutical company developing taurolidine-based anti-infective therapies intended to prevent catheter- and device-related infections. Major long-term growth drivers include regulatory approvals, successful commercialization and hospital adoption in dialysis and surgical settings, and partnership or licensing agreements that could broaden distribution; investors may find the company appealing because it targets a clear clinical need with measurable endpoints and potential cross-market use.

The most important investment risks are clinical and regulatory failure, ongoing need for external financing to fund development and commercialization, and limited commercial track record combined with competitive adoption challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.37
Dividend Yield
-
Revenue TTM
462.25M
Revenue Per Share
5.91
Gross Profit TTM
417.00M
Debt / Equity
0.37
ROE
54.93%
Net Debt
3.09M
ROCE
23.03%
Diluted EPS TTM
2.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 150.02M -19.32M -46.34M -30.29M -29.46M
Net income 163.06M -17.93M -46.34M -29.70M -28.21M
Selling general administrative 68.22M 29.96M 17.69M 20.01M 16.35M
Selling and marketing expenses 38.05M 28.74M 18.12M - -
Gross profit 275.75M 40.28M -0.21M 0.06M 0.04M
Reconciled depreciation 14.55M 0.31M 0.07M 0.08M 0.06M
Ebit 150.14M -19.29M -46.30M -30.62M -29.44M
Ebitda 165.13M -18.98M -46.23M -30.30M -29.44M
Depreciation and amortization 14.99M 0.31M 0.07M 0.33M -0.01M
Non operating income net other - - - - -0.02M
Operating income 150.14M -22.36M -48.96M -30.62M -29.44M
Other operating expenses 161.57M 65.83M 48.96M 30.69M 29.48M
Interest expense 2.78M 0.04M 0.03M 0.03M 0.02M
Tax provision -13.04M -1.39M 0.00M -0.59M -1.25M
Interest income 3.85M 2.58M 2.68M 0.33M 0.01M
Net interest income 1.06M 2.54M 2.65M 0.30M -0.00M
Income tax expense -13.04M -1.39M -0.00M -0.59M -1.25M
Total revenue 311.71M 43.47M 0.00M 0.07M 0.19M
Total operating expenses 125.61M 62.64M 48.75M 30.69M 29.48M
Cost of revenue 35.96M 3.19M 0.21M 0.00M 0.15M
Total other income expense net -0.12M 3.03M 2.62M 0.34M -0.02M
Net income from continuing ops 163.06M -17.93M -46.34M -29.70M -28.21M
Net income applicable to common shares - - - -29.70M -28.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 826.14M 118.85M 82.06M 62.04M 68.95M
Intangible assets 379.07M 1.84M - - -
Other current assets 7.86M 3.63M 1.24M 0.62M 0.72M
Total liab 420.83M 34.19M 11.92M 6.98M 6.15M
Total stockholder equity 405.31M 84.66M 70.14M -275.36M -245.66M
Other current liab 164.94M 31.95M 6.97M 3.97M 3.01M
Common stock 0.08M 0.06M 0.05M 0.04M 0.04M
Capital stock 0.08M 0.06M 0.06M 0.04M 0.04M
Retained earnings -176.57M -339.63M -321.70M -275.36M -245.66M
Good will 30.00M 1842.31M - - -
Other assets 50.32M -118726.83M 0.00M 0.53M 0.77M
Cash 145.82M 40.65M 43.72M 43.37M 53.55M
Total current liabilities 174.27M 33.84M 11.40M 6.31M 5.35M
Net debt 3.09M -40.13M -43.05M -42.57M -52.63M
Short term debt 1.45M 0.17M 0.15M 0.13M 0.12M
Short long term debt total 148.91M 0.52M 0.67M 0.80M 0.92M
Other stockholder equity 581.80M 424.13M 391.69M -0.13M -0.13M
Property plant equipment - - - 2.38M 1.47M
Total current assets 350.47M 114.58M 79.45M 59.55M 66.47M
Long term investments 10.36M 0.00M - - -
Net tangible assets - - - 55.06M 62.80M
Short term investments 3.69M 11.04M 32.39M 15.64M 12.15M
Net receivables 171.23M 51.65M - 0.00M 0.05M
Long term debt 144.63M - - - -
Inventory 29.72M 7.60M 2.11M 0.00M 0.00M
Accounts payable 7.88M 1.72M 4.28M 2.20M 2.21M
Accumulated other comprehensive income 0.00M 0.09M 0.09M 0.08M 0.09M
Common stock total equity - - - - 0.04M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - -245.66M
Non currrent assets other -9.93M 0.11M -0.00M 0.10M 0.10M
Non current assets total 425.35M 4.27M 2.61M 2.49M 2.48M
Capital lease obligations 4.29M 0.52M 0.67M 0.80M 0.92M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 2.34M 21.23M -17.06M -3.71M -7.71M
Change to liabilities - - - -0.01M 1.08M
Total cashflows from investing activities -308.43M 21.23M -17.06M -3.71M -9.13M
Net borrowings 150.00M 0.00M - - -
Total cash from financing activities 238.45M 26.32M 55.92M 17.90M 41.76M
Change to operating activities - - - 1.03M 0.65M
Net income 163.06M -17.93M -46.34M -29.70M -28.21M
Change in cash 105.07M -3.07M 0.45M -10.18M 11.45M
Begin period cash flow 40.76M 43.82M 43.37M 53.55M 42.10M
End period cash flow 145.82M 40.76M 43.82M 43.37M 53.55M
Total cash from operating activities 175.05M -50.61M -38.41M -24.36M -21.16M
Issuance of capital stock 90.16M 18.88M 55.83M 17.77M 41.46M
Depreciation 14.55M 0.31M 0.07M 0.08M 0.06M
Other cashflows from investing activities - -0.12M - - -9.13M
Change to inventory -3.48M -5.49M -2.11M 0.00M 0.15M
Change to account receivables -90.92M -51.79M 0.00M 0.04M -0.04M
Sale purchase of stock - - -0.20M - 41.76M
Other cashflows from financing activities -2.18M 7.44M 0.09M 0.13M 0.30M
Change to netincome - - - 4.19M 5.04M
Capital expenditures 2.26M 0.12M 0.33M 0.22M 1.43M
Change receivables - - - - -0.04M
Cash flows other operating - - - - 0.77M
Exchange rate changes - - - - -0.01M
Cash and cash equivalents changes - - - - 11.45M
Change in working capital 7.27M -39.41M 2.23M 1.07M 1.84M
Stock based compensation 13.83M 6.13M 5.49M 4.07M 5.04M
Other non cash items 4.72M 0.28M 0.13M 0.12M 7.06M
Free cash flow 172.79M -50.73M -38.74M -24.58M -22.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CRMD
CorMedix Inc		 -0.07
1.30%		 5.30 3.63 47.85 1.31 1.33 1.10 1.97
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

389 Interpace Pkwy, Parsippany, NJ, United States, 07054

908 517 9500

https://cormedix.com

191

Name Title Year Born
Dr. Matthew T. David M.D. Exec. VP & CFO 1978
Dr. Phoebe Mounts Esq., Ph.D. EVP, Gen. Counsel, Head of Regulatory, Compliance, Legal & Technical Operations and Sec. 1950
Ms. Elizabeth Masson-Hurlburt B.A. Exec. VP & Head of Clinical Operations 1979
Mr. Joseph Todisco MBA CEO & Director 1976
Donna Ucci Sr. VP & Head of Global Quality NA
Mr. Joseph Todisco MBA CEO & Director 1977
Dr. Matthew T. David M.D. Executive VP & CFO 1979
Ms. Erin Mistry Executive VP & Chief Commercial Officer 1983
Ms. Elizabeth Masson-Hurlburt B.A. Executive VP and Chief Clinical Strategy & Operations Officer 1980
Ms. Kaufman Beth Zelnick Esq. Executive VP, Chief Legal Officer & Corporate Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…